- Home
- BTE vs IDYA Comparison
BTE vs IDYA Comparison
Compare BTE & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BTE
- IDYA
- Stock Information
- Founded
- BTE 1993
- IDYA 2015
- Country
- BTE Canada
- IDYA United States
- Employees
- BTE N/A
- IDYA N/A
- Industry
- BTE Meat/Poultry/Fish
- IDYA Biotechnology: Pharmaceutical Preparations
- Sector
- BTE Consumer Staples
- IDYA Health Care
- Exchange
- BTE Nasdaq
- IDYA Nasdaq
- Market Cap
- BTE 1.3B
- IDYA 1.5B
- IPO Year
- BTE N/A
- IDYA 2019
- Fundamental
- Price
- BTE $1.62
- IDYA $19.89
- Analyst Decision
- BTE Hold
- IDYA Strong Buy
- Analyst Count
- BTE 1
- IDYA 12
- Target Price
- BTE $5.50
- IDYA $54.27
- AVG Volume (30 Days)
- BTE 46.2M
- IDYA 1.5M
- Earning Date
- BTE 05-05-2025
- IDYA 05-06-2025
- Dividend Yield
- BTE 3.99%
- IDYA N/A
- EPS Growth
- BTE N/A
- IDYA N/A
- EPS
- BTE 0.28
- IDYA N/A
- Revenue
- BTE $2,327,227,884.00
- IDYA $7,000,000.00
- Revenue This Year
- BTE $3.43
- IDYA $68.39
- Revenue Next Year
- BTE N/A
- IDYA $324.54
- P/E Ratio
- BTE $5.59
- IDYA N/A
- Revenue Growth
- BTE 10.55
- IDYA N/A
- 52 Week Low
- BTE $1.36
- IDYA $13.45
- 52 Week High
- BTE $3.84
- IDYA $44.42
- Technical
- Relative Strength Index (RSI)
- BTE 45.13
- IDYA 58.60
- Support Level
- BTE $1.56
- IDYA $19.26
- Resistance Level
- BTE $1.95
- IDYA $20.46
- Average True Range (ATR)
- BTE 0.09
- IDYA 0.97
- MACD
- BTE 0.01
- IDYA 0.17
- Stochastic Oscillator
- BTE 14.10
- IDYA 84.25
About BTE Baytex Energy Corp
Baytex Energy Corp is an oil and gas company. Geographically, the group operates in Canada and the United States. The company derives a majority of revenue from Canada. Its Canada segment includes the exploration, development, and production of crude oil and natural gas in Western Canada.
About IDYA IDEAYA Biosciences Inc.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.